NCT00268853已完成2 期
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone Plus Rituximab (CPOP-R) in Patients With Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 124
- 试验地点
- 75
- 主要终点
- Response Rate
研究概览
简要总结
The purpose of this study is to compare the standard CHOP-R regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab to CPOP-R (same regimen, but substituting Doxorubicin with Pixantrone). The objective is to show that CPOP-R is not inferior to CHOP-R.
详细描述
In preclinical studies, pixantrone has shown significantly less cardiotoxicity than other anthracyclines or anthracenediones. In addition, patients with relapsed disease, who have received prior maximum doses of anthracyclines, have tolerated high doses of pixantrone with minimal added cardiotoxicity. Pixantrone is currently being studied in a Phase III study in 3rd line aggressive NHL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previously untreated and histologically confirmed diffuse large B-cell lymphoma according to REAL/WHO classification.
- •Stage II, III or IV disease
- •Age ≥ 18 years
- •ECOG performance status ≤ 2
- •At least one objectively bidimensionally measurable lesion as demonstrated by CT, spiral CT, or MRI that can be followed for response as target lesion. Patients with the following sites of disease are NOT eligible:
- •Patients with only skin lesions or only palpable lymph nodes.
- •Patients with spleen or bone marrow as only site of disease.
- •Life expectancy ≥ 3 months
- •Serum bilirubin ≤ 1.5 x the institution's upper limit normal (ULN) and creatinine ≤ 2.0 ULN and AST or ALT ≤ 2.0 x the institution's ULN. If hepatic involvement by lymphoma is present, AST or ALT may be ≤ 5.0 x the institution's ULN.
- •LVEF ≥ 50% determined by MUGA scan.
- •Ability to comply with the visit schedule and assessments required by the protocol.
- •Signed approved informed consent, with understanding of study procedures.
排除标准
- •Any prior chemotherapy (except intrathecal chemotherapy at diagnosis and pretreatment corticosteroid therapy) or radiotherapy: Patients may receive corticosteroid pretreatment therapy for up to 7 days after randomization, pending Investigator's decision to reduce tumor burden.
- •Histological diagnosis of T-cell lymphoma or any B-cell lymphoma other than diffuse large B-cell.
- •History of indolent lymphoma
- •Active CNS involvement based on clinical evaluation .
- •HIV-related lymphoma.
- •Major thoracic and/or abdominal surgery within the 4 weeks before randomization from which the patient has not fully recovered except for diagnosis of NHL. Patients who have had minor surgery may be enrolled after a ≥ 1 week recovery period except for diagnosis of NHL.
- •Clinically significant cardiovascular abnormalities
- •Serious (NCI CTCAE grade 3-4) intercurrent infection at randomization or deep seated or systemic mycotic infections.
- •Clinical symptoms suggesting unresolved HIV, HBV or HCV infection. Patients with seropositivity presumed to be due to prior vaccination against Hepatitis B virus or resolved infection will not be excluded.
- •Active or history of another malignancy except cured basal cell carcinoma of skin or carcinoma in situ of uterine cervix. Patients who have been in remission from another previous malignancy for >5 years will be considered eligible.
- •Known hypersensitivity to the excipients or the study drugs that the patient will receive.
- •Any contraindications to the study drugs as described in the Summary of Product Characteristics or package inserts.
- •Neurological contraindication to vincristine (e.g. peripheral neuropathy).
- •Any condition which, in the judgment of the Investigator, would place the subject at undue risk, interfere with the results of the study, or make the subject otherwise unsuitable.
- •General status that, in the opinion of the Investigator does not permit the administration of eight courses of CHOP-R/CPOP-R.
- •Treatment with any other investigational study drug within 30 days before randomization. Patient must have recovered from all side effects of other investigational therapy.
- •Potentially fertile men and women and their sexual partners not willing to use adequate contraception as defined by the Investigator during the study and for 6 months after the last day of study drug administration.
- •Any circumstance at the time of study entry that would preclude completion of the study or the required follow-up.
研究组 & 干预措施
1
Experimental
干预措施: CPOP-R (Drug)
2
Active Comparator
干预措施: CHOP-R (Drug)
结局指标
主要结局
Response Rate
时间窗: Subjects followed for 5 years post treatment
次要结局
- Overall Survival(The interval between the date of randomization and death due to any cause (up to 100 weeks))
- Median Progression Free Survival (PFS)(From the date of randomization to the first documented disease progression or death (up to 100 weeks))
- Overall Objective Response Rate(Subjects followed for 5 years post treatment)
- Time to Treatment Failure(Subjects followed for 5 years post treatment)
研究者
研究点 (75)
Loading locations...
相似试验
已完成
3 期
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast CancerBreast CancerNCT00041119Alliance for Clinical Trials in Oncology3,871
Unknown
3 期
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCLLymphoma, Mantle-CellNCT00209222European Mantle Cell Lymphoma Network360
已完成
2 期
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaLymphomaNCT00513955University Hospital Plymouth NHS Trust50
Unknown
3 期
R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell LymphomaLymphoma, Large B-Cell, DiffuseNCT02428751Wenqi Jiang216
终止
3 期
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell LymphomaLymphoma, Large-Cell, DiffuseNCT00135499Lymphoma Study Association138